VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for The Female Health Company (VERU Inc.) for the period ended December 31, 2009. The Company manufactures, markets, and distributes the FC2 Female Condom, the only FDA-approved product under a woman's control for preventing pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. During this quarter, the Company completed the transition from its first-generation product (FC1) to the second-generation product (FC2), ceasing FC1 production in October 2009.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 3% ($143,836) driven by a 20% increase in unit sales. The sales mix shifted significantly to the lower-cost FC2 product (93% of mix vs. <50% in the prior year).
• Margin Expansion: Gross margin improved to 58.4% from 45.7% due to the lower production costs of the FC2 nitrile polymer compared to the FC1 polyurethane.
• Restructuring Costs: The Company incurred a one-time restructuring charge of $1,896,353 related to the cessation of FC1 manufacturing in the U.K. and the surrender of the U.K. facility lease. This charge turned an operating profit into an operating loss.
• Foreign Currency: The prior year included a $1.19 million foreign currency gain. In the current quarter, the U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currency, resulting in a modest foreign currency transaction loss of $48,689.
• Accounts Receivable: Decreased significantly from $7.8 million to $4.1 million, attributed to the lower unit price of FC2 and the timing of large order shipments.

Guidance, Outlook, and Risks

• Dividend Declaration: On January 14, 2010, the Board declared the Company's first-ever quarterly cash dividend of $0.05 per share, payable February 16, 2010. The Company expects to pay approximately $1.4 million from cash on hand.
• Outlook: Management expects to incur up to $200,000 in additional restructuring costs. The Company believes its current cash position is adequate for near-term operations but may sell equity or borrow under its Heartland Bank credit facility (up to $1.5 million available) if needed.
• Risks:
  • Single Product Reliance: The Company relies almost entirely on the FC2 Female Condom for revenue.
  • Regulatory Risk: FC2 is a Class III medical device; failure to comply with FDA regulations could result in withdrawal of approval.
  • Market Dependence: Success depends on public sector funding (e.g., USAID, UNAIDS) and the ability of commercial partners to market the product effectively.
  • Lease Uncertainty: The new U.K. lease has an uncertain term; if terminated early, up to $246,000 of the restructuring charge could be reversed.

Investor Verification Checklist

• Dividend Sustainability: Verify if the $1.4 million dividend payment impacts liquidity given the net loss and upcoming lease payments.
• Restructuring Finality: Confirm the final status of the U.K. lease exit and whether the potential $246,000 reversal of charges will materialize.
• FC2 Adoption Rates: Monitor the transition of major public sector customers (e.g., USAID, NACO) from FC1 to FC2 to ensure revenue stability.
• Cash Flow vs. Net Income: Note the divergence between the net loss and positive operating cash flow ($441k), driven by working capital changes rather than core profitability.
• Stock Repurchase Program: Review the remaining capacity of the share repurchase program (1,146,189 shares remaining) and recent buyback activity.